Compare TEAM & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEAM | EW |
|---|---|---|
| Founded | 2002 | 1958 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3B | 49.5B |
| IPO Year | 2015 | 2000 |
| Metric | TEAM | EW |
|---|---|---|
| Price | $158.16 | $85.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 27 | 20 |
| Target Price | ★ $249.77 | $95.83 |
| AVG Volume (30 Days) | 2.1M | ★ 2.9M |
| Earning Date | 01-29-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.33 |
| Revenue | $5,460,076,000.00 | ★ $5,883,800,000.00 |
| Revenue This Year | $23.46 | $14.29 |
| Revenue Next Year | $18.56 | $9.68 |
| P/E Ratio | ★ N/A | $36.13 |
| Revenue Growth | ★ 19.51 | 10.60 |
| 52 Week Low | $139.70 | $65.94 |
| 52 Week High | $326.00 | $87.89 |
| Indicator | TEAM | EW |
|---|---|---|
| Relative Strength Index (RSI) | 49.62 | 55.32 |
| Support Level | $158.04 | $83.66 |
| Resistance Level | $164.68 | $87.44 |
| Average True Range (ATR) | 4.75 | 1.45 |
| MACD | -0.83 | -0.14 |
| Stochastic Oscillator | 53.25 | 75.63 |
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.